Suzhou Abogen Biosciences

Biohaven’s stock price closed down 15.2% at $19.84 on 25 April on the news that the company withdrew its application for European Medicines Agency approval of troriluzole in the treatment of spinocere

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

China has granted the country’s first emergency use authorization (EUA) to a messenger RNA vaccine for COVID-19, approving SYS6006 developed by domestic firm CSPC Pharmaceutical Group Limited for th

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue